Informações:
Falhas:
ID
34157
Descrição
A Study of Herceptin (Trastuzumab) in Combination With Whole Brain Radiotherapy in Patients With HER-2 Positive Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01363986
Link
https://clinicaltrials.gov/show/NCT01363986
Palavras-chave
Versões (1)
- 14/01/2019 14/01/2019 -
Titular dos direitos
see on clinicaltrials.gov
Transferido a
14 de janeiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Breast Cancer NCT01363986
Eligibility Breast Cancer NCT01363986
- StudyEvent: Eligibility
Similar models
Eligibility Breast Cancer NCT01363986
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
ID.1
Item
adult patients, >/=18 years of age
boolean
ID.2
Item
diagnosis of breast carcinoma with her-2 overexpression
boolean
ID.3
Item
at least one measurable brain metastasis
boolean
ID.4
Item
patients for whom, according to investigator assessment, whole brain radiotherapy is the best therapeutic option
boolean
ID.5
Item
performance status (who) </=2
boolean
ID.6
Item
life expectancy >/=3 months
boolean
ID.7
Item
presence of neoplastic meningitis
boolean
ID.8
Item
any prior radiotherapy to the brain
boolean
ID.9
Item
patients for whom, according to investigator assessment, stereotactic radiotherapy is the best therapeutic option
boolean
ID.10
Item
previous neoplasms, other than breast carcinoma, within 5 years since enrolment
boolean